SeaStar Medical Announces Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury at International Symposium
Reuters
Sep 29
SeaStar Medical Announces Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury at International Symposium
SeaStar Medical Holding Corporation has announced positive preliminary results from its SAVE Surveillance Registry, evaluating the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in pediatric patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy. The results were presented at the 5th International Symposium on Acute Kidney Injury in Children. Data from the first 21 pediatric patients showed no device-related adverse events or infections and no reports of immunosuppressive effects. Survival rates were reported at 76% for both Day 28 and Day 60, and 71% at Day 90. The SAVE Registry is designed to collect real-world evidence from up to 300 patients and aims to confirm the safety and efficacy of QUELIMMUNE therapy. SeaStar Medical plans to use these findings to support broader adoption of the therapy and to inform ongoing clinical trials in adult populations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536489-en) on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.